Wnt/β-catenin pathway as a potential target for Parkinson’s disease: a cohort study of romosozumab using routinely collected health data in Japan

IntroductionRomosozumab is a monoclonal antibody approved for osteoporosis which targets sclerostin, an endogenous inhibitor of Wnt/β-catenin pathway. Given the essential roles of the Wnt/β-catenin pathway in various tissues, we hypothesized romosozumab treatment may influence other conditions.Metho...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Shoichiro Inokuchi, Koji Shimamoto
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	osteoporosis electronic health records drug repositioning Wnt signaling pathway Parkinson disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1411285/full